Neurogene (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 739 Shares

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 739 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $34.06, for a total value of $25,170.34. Following the completion of the transaction, the chief financial officer owned 92,901 shares of the company’s stock, valued at approximately $3,164,208.06. The trade was a 0.79% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The shares were sold at an average price of $34.82, for a total value of $141,404.02.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total transaction of $300,000.00.

Neurogene Trading Up 4.3%

Shares of NASDAQ NGNE opened at $35.34 on Friday. The company has a 50 day simple moving average of $29.23 and a two-hundred day simple moving average of $23.25. The stock has a market cap of $558.37 million, a price-to-earnings ratio of -7.77 and a beta of 1.68. Neurogene Inc. has a 12 month low of $15.93 and a 12 month high of $37.27.

Neurogene (NASDAQ:NGNE) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). Analysts forecast that Neurogene Inc. will post -5.63 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NGNE. HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Neurogene in a research note on Tuesday, June 9th. Canaccord Genuity Group dropped their target price on Neurogene to $180.00 and set a “buy” rating on the stock in a report on Monday, April 6th. UBS Group set a $70.00 price target on Neurogene in a research report on Wednesday, June 3rd. Guggenheim assumed coverage on Neurogene in a report on Tuesday, April 28th. They issued a “buy” rating and a $69.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $84.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after acquiring an additional 1,059 shares in the last quarter. Bank of America Corp DE increased its stake in shares of Neurogene by 81.6% in the 2nd quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock valued at $1,426,000 after purchasing an additional 42,880 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in Neurogene by 24.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock worth $88,000 after purchasing an additional 1,000 shares during the period. Blair William & Co. IL raised its holdings in Neurogene by 6.4% in the 3rd quarter. Blair William & Co. IL now owns 141,820 shares of the company’s stock worth $2,458,000 after purchasing an additional 8,584 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in Neurogene by 89.8% during the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after purchasing an additional 978 shares in the last quarter. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.